This post hoc analysis evaluated the dose-related effects of sodium oxybate on sleep continuity and nocturnal sleep quality in patients with narcolepsy-cataplexy. Polysomnography data, including shifts to Stage N1/Wake, were from a randomized, placebo-controlled trial of sodium oxybate. Patients were ≥16 years old with a diagnosis of narcolepsy including symptoms of cataplexy and excessive daytime sleepiness. Treatment was for 8 weeks with placebo or sodium oxybate 4.5, 6 or 9 g administered as two equally divided nightly doses. Relative to baseline, significant dose-dependent reductions in the number of shifts per hour from Stages N2/3/rapid eye movement and Stages N2/3 to Stage N1/ Wake were observed at week 8 with sodium oxybate (P < 0.05); sodium oxybate 6-and 9-g doses also resulted in similar reductions in shifts per hour of rapid eye movement to Stage N1/Wake (both P < 0.05). Across all shift categories, the shift reductions with sodium oxybate 9 g were significantly greater than those observed with placebo (P < 0.05). Improvements from baseline in reported sleep quality were significantly greater with sodium oxybate 4.5 and 9 g at week 8 (P < 0.05). Correlations between change from baseline in number of shifts per hour to Stage N1/Wake and cataplexy frequency, patient-reported nocturnal sleep quality, and excessive daytime sleepiness assessed using the Epworth Sleepiness Scale were numerically highest for the sodium oxybate 9-g dose across all sleep stage shift categories. In these patients with narcolepsy, sodium oxybate showed improvements in the sleep continuity and nocturnal sleep quality that are characteristic of disrupted nighttime sleep (ClinicalTrials.gov identifier NCT00049803).
IN TROD UCTI ON
Type 1 narcolepsy is a chronic disorder characterized by excessive sleepiness and cataplexy (American Academy of Sleep Medicine, 2014) . Hypnagogic hallucinations and sleep paralysis are also common, as is a fifth disease-related symptom, disrupted nighttime sleep (DNS), a frequent complaint reported by patients as well as an objective finding on polysomnography (PSG); DNS is considered in the literature as part of the narcolepsy syndrome (American Academy of Sleep Medicine, 2014; Dauvilliers et al., 2007; Roth et al., 2013) . Although DNS is prevalent in narcolepsy (Roth et al., 2013) , it has received less attention than other symptoms in understanding its role in narcolepsy pathophysiology or its importance for effective therapy. Furthermore, the relationship of DNS with other narcolepsy symptoms has rarely been investigated. A recent literature review on the nature of DNS in patients with narcolepsy, in terms of both PSG and patient reports, summarized that patients with narcolepsy experience frequent brief awakenings, arousals, and elevated Stage N1 sleep that is also associated with poor nocturnal sleep quality (Roth et al., 2013) . The sleep disturbance of narcolepsy generally differs from that of insomnia in that patients with insomnia often report long sleep-onset latency with one or two prolonged periods of wakefulness during the night, whereas the sleep-onset latency is short in narcolepsy with frequent brief awakenings and arousals but also with frequent prolonged time awake after sleep onset (Roth et al., 2013) . The frequency of sleep stage shifts to Wake and Stage N1, and whether sleep stage shifts differentially arise from rapid eye movement (REM) or non-REM (NREM) sleep have not been well characterized in narcolepsy. These are important concepts with regard to their role in DNS, which has been identified by a consensus panel not only as a symptom relevant from the clinical and patient perspectives, but also as a potential target for treatment (Roth et al., 2013) .
Sodium oxybate (SXB) is a sodium salt of c-hydroxybutyrate, an endogenous metabolite of c-aminobutyric acid (GABA); SXB is approved for the treatment of excessive daytime sleepiness (EDS) in narcolepsy and for the treatment of cataplexy in narcolepsy [Xyrem; Xyrem â (sodium oxybate)
Oral Solution, 2015] . A study that evaluated the effects of SXB on sleep in narcolepsy showed a dose-dependent decrease in time spent in Wake and NREM Stage N1, and increases in Stage N3 (Black et al., 2010) . Studies have also shown that SXB increased slow-wave sleep with decreased nighttime awakenings in healthy normal subjects (Lapierre et al., 1990) , and increased slow-wave sleep without suppression of REM sleep in patients with insomnia and other conditions (Boscolo-Berto et al., 2012; Mamelak et al., 1973 Mamelak et al., , 1977 Ondo et al., 2008) , although SXB is not indicated for these uses. However, while early studies suggested the importance of the improvement of sleep fragmentation during treatment with SXB (Broughton and Mamelak, 1979; Lammers et al., 1993) , the question remains as to what happens to sleep stage shifts related to Wake and Stage N1, which was not directly addressed in previous studies, and whether or not these parameters correlate with narcolepsy symptoms or patient-reported evaluation of nocturnal sleep quality in patients with narcolepsy. The primary purposes of this post hoc analysis of an SXB clinical trial were to expand on a previous analysis by evaluating the dose-related effects of SXB on key PSG parameters associated with DNS in narcolepsy, specifically the frequency of sleep stage shifts to Stages Wake and N1. An additional goal was to study within dose groups the relationship between the PSG-observed nighttime shifts and symptoms of EDS, cataplexy and poor nocturnal sleep quality in patients with narcolepsy.
MATERI ALS AND METHODS

Design
This was a post hoc analysis of PSG data obtained during a phase 3, randomized, placebo-controlled trial performed in 2002 evaluating SXB for the treatment of EDS and cataplexy in patients with narcolepsy. The study from which these data were taken was performed in accordance with the Declaration of Helsinki, and all patients provided written informed consent prior to participation. Results on outcomes of sleepiness, cataplexy measures, sleep architecture and safety have already been reported (Black et al., 2010; Xyrem International Study Group, 2005a,b) .
Full details of the study design and methods have been previously published (Xyrem International Study Group, 2005a) . In brief, the sample consisted of patients ≥16 years old with a diagnosis of narcolepsy with cataplexy based on clinical history, an overnight PSG, and a multiple sleep latency test. These patients were randomized to 8 weeks of treatment with placebo or SXB 4.5, 6 or 9 g administered as two equally divided nightly doses; the second dose was taken 2.5-4 h after the first dose. Patients receiving SXB 6-and 9-g doses per night were titrated in weekly 1.5-g increments.
The treated sample in the original study consisted of 228 patients. In the current analysis, data were available from 159 patients who had evaluable sleep stage data and for 211 patients with evaluable nocturnal sleep quality; these numbers reflect patients who had data at both baseline and week 8. The evaluable PSG data were only available from 159 patients, as the data for the other patients were either lost or the digital files were corrupted and/or unreadable. To our knowledge, the data loss was random; group differences reflect the numbers in the group for the intent-to-treat population in the original study (Xyrem International Study Group, 2005a ).
Outcomes
The current analysis focuses on PSG data to specifically characterize fragmented sleep as manifested by shifts associated with both NREM and REM sleep to Stage N1 or Wake and the correlation of these data with nocturnal sleep quality and other narcolepsy symptoms. Specifically, PSG outcomes included the number of shifts per hour from Stages N2/3/REM to Stage N1/Wake, Stages N2/3 to Stage N1/ Wake, and REM to Stage N1/Wake. These outcomes were defined, respectively, as total number of shifts per night from Stages N2/3/REM to Stage N1/Wake divided by total time in hours spent in Stages N2/3/REM during the night; total number of shifts per night from Stages N2/3 to Stage N1/ Wake divided by total time in hours spent in Stages N2/3 during the night; and total number of shifts per night from Stage REM to Stage N1/Wake divided by total time in hours spent in Stage REM during the night.
Patient-reported quality of nocturnal sleep, determined as an average over the prior 2 weeks, was rated using a fourpoint Likert-type scale (0 = Excellent; 1 = Good; 2 = Fair; 3 = Poor). The change from baseline at week 8 for these outcomes was determined for placebo and all SXB doses.
Statistical analyses
The frequency distributions of number of stage shifts per hour of sleep at baseline and week 8 were plotted as histograms for placebo and for the pooled SXB patients to provide visualization of changes in shifts with treatment. The statistical significance of within-group changes from baseline was evaluated using a paired t-test. Analysis of covariance models with treatment as a factor and baseline value as a covariate were used to evaluate response comparisons of SXB versus placebo for differences from baseline to week 8 in shifts per hour and nocturnal sleep quality. Correlation analyses were performed using Spearman correlation coefficients for the relationship between changes in shifts at week 8 and three clinical features, including patient-reported frequency of cataplexy, patient-reported nocturnal sleep quality, and EDS assessed using the Epworth Sleepiness Scale (ESS; Johns, 1991) . All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
RESUL TS Sample characteristics
Demographic characteristics of the sample according to treatment (Table 1) show that patients were primarily female (52.0-71.7%), with a mean age that ranged across treatment groups from 40.2 to 42.1 years. These patients were representative of the total sample in the original trial, which was 65.4% female, with an average age of 40.5 years.
PSG analyses
Among the 159 patients, treatment with SXB was characterized by fewer shifts from Stages N2/3/REM to Stage N1/ Wake in a larger number of patients relative to baseline, with a greater clustering of patients with lower number of shifts at week 8 (Fig. 1a) . In contrast, the overall range and distribution of shifts in the placebo group was generally similar between the two assessment points (Fig. 1a) . Similarly, for shifts from Stages N2/3 to Stage N1/Wake, there was a greater clustering of patients at lower number of shifts at week 8 relative to baseline with SXB, with fewer changes in the pattern between baseline and week 8 observed with placebo (Fig. 1b) . For shifts from REM to Stage N1/Wake, both SXB and placebo showed a greater clustering of patients at lower number of shifts at week 8 relative to baseline, although placebo was characterized by a wider range in number of shifts per hour (Fig. 1c) .
Consistent with the results suggested by the frequency of shifts, significant reductions from baseline in the mean number of shifts per hour were observed for all three shift categories across SXB doses (P < 0.05; Fig. 2) ; in contrast, none of the changes from baseline was significant in the placebo group. These reductions appeared to be dose dependent, with the greatest effects observed at the SXB 9-g per night dose (Fig. 2) .
Relative to placebo, significantly greater reductions in shifts were observed with SXB 9 g across all three shift categories (P < 0.05; Fig. 2 ). The reductions observed with SXB 6 g were also significantly greater than the reductions with placebo for shifts from Stages N2/3/REM and Stages N2/3 to Stage N1/Wake (P < 0.05), but not for shifts from REM to Stage N1/Wake. There were no significant differences from placebo with the SXB 4.5-g dose.
Quality of nocturnal sleep
Improvements from baseline in patient-reported nocturnal sleep quality were observed with all doses of SXB at week 8 (P < 0.001; Fig. 3 ). These improvements were significantly greater than those reported with placebo (P < 0.05), with the greatest improvement observed with SXB 9 g (Fig. 3) .
Stage shift correlations
Correlation analyses were performed within dose groups to describe the relationship between: (a) change from baseline in number of shifts per hour (from REM, from Stages N2/3, and from Stages N2/3/REM) to Stage N1/Wake; and (b) change from baseline for three clinical features (frequency of cataplexy, nocturnal sleep quality and ESS). For ESS (Table 2) , correlations were numerically higher with increased dose for shifts from Stages N2/3/REM and from Stages N2/3 to Stage N1/Wake, but not for shifts from REM to Stage N1/Wake. For cataplexy (Table 3) , the highest Spearman r-values were seen for shifts from REM sleep with the 6-and 9-g doses, 0.271 and 0.366, respectively. Finally, quality of nocturnal sleep correlated with total number of shifts from Stages N2/3/REM with SXB 6-and 9-g doses, 0.242 and 0.378, respectively, with Spearman r-values that were similar or lower for shifts from either Stages N2/3 or shifts from REM to Stage N1/Wake (Table 4) .
DISCUSSION
This analysis reports on the treatment effects of SXB on both fragmented sleep and narcolepsy symptoms including nocturnal sleep quality among patients with narcolepsy with evaluable sleep stage data at baseline and during follow-up (Christensen et al., 2015; Pizza et al., 2015; Sorensen et al., 2013) . The original trial reports characterized dose-dependent increases in the time spent in sleep Stages N2 and N3 as well as reductions in the number of nocturnal awakenings that were significant relative to placebo for the 6-and 9-g doses (Black et al., 2010) . The current analysis evaluated the sleep stage shifts from deeper to lighter sleep (N1) or Wake as an indicator of sleep fragmentation and showed that SXB reduces fragmented sleep, with the 9-g dose associated with the greatest effects across the PSG outcomes and patientreported nocturnal sleep quality. This reduced sleep fragmentation was demonstrated by significant reductions in the number of shifts from Stages N2/3/REM to Stage N1/Wake across SXB doses relative to placebo. When stratified by NREM and REM fragmentation, significant reductions were observed in shifts from both NREM (Stages N2/3) and REM components. These results, combined with the previously reported increase in time spent in Stages N2 and N3, may suggest that SXB consolidates and deepens sleep in patients with narcolepsy-cataplexy.
The 9-g dose resulted in shift reductions that were consistently significantly greater than placebo. While weak to moderate correlations were observed between changes in shifts and cataplexy, nocturnal sleep quality, and ESS, the 9-g dose consistently resulted in correlations that were numerically higher for these outcomes. It is possible that the effects on stage shifts are only moderately correlated with these measures due to the relatively short duration of treatment in this study, as a long-term study of SXB in narcolepsy has demonstrated median times to maximum response of 106 days (range 85-164 days) for EDS and 213 days (range 94-279 days) for cataplexy (Bogan et al., 2015) . Including a larger sample with more varied levels of these symptoms and a longer follow-up period would provide further understanding of these correlations.
Patient-reported quality of nocturnal sleep was also significantly improved with SXB, relative to both baseline and placebo. While these improvements may not be unexpected based on the effect of SXB to objectively consolidate sleep and reduce nocturnal awakenings [Xyrem ( 2015] , there was only moderate correlation between nocturnal sleep quality and shifts to Stage N1/Wake, and only at the highest approved SXB dose (possibly due to the relatively short duration of the current study compared with the time until maximum efficacy). Of interest, the number of shifts from REM sleep to Stage N1/Wake correlated with the frequency of cataplexy in a dose-dependent manner. However, although these data support the relationship between cataplexy and REM sleep, this is not a robust correlation. While the mechanism of how SXB modulates sleep consolidation has not been fully elucidated, it is possible that the decrease in sleep stage shifts results from proposed pharmacological effects observed across NREM, REM and wakefulness, resulting in deeper sleep, rather than from induction of non-physiological delta wave activity during sleep (Vienne et al., 2012) . As noted in a recent review of DNS, other narcolepsy drugs such as stimulants do not show such an effect, as sleep patterns associated with DNS are present regardless of stimulant use (Roth et al., 2013) . These results warrant further evaluation, and a possible approach is a comparison of the sleep-consolidating effects of SXB relative to classic hypnotic sleep agents such as zolpidem or zopiclone. The clinical relevance of these findings has yet to be characterized, and SXB is not currently approved for the treatment of DNS.
The main limitation of this study is that it was a post hoc analysis that relied on data available from only a proportion of the original study sample, potentially reducing sensitivity. The post hoc nature of the analysis combined with an inability to appropriately adjust for multiple comparisons also resulted in the decision to not present P-values for the correlations, representing another study limitation. Additionally, there are no PSG data to evaluate the presence of, or explain the origin of, potential sleep-related fragmentation manifestations such as periodic leg movements during sleep and apnea-hypopnea at baseline, which may be subsequently affected by SXB in an unknown manner. Similarly, it is sometimes difficult to differentiate N1 from REM sleep in patients with narcolepsy, especially when muscle tone is enhanced in REM sleep as may occur in these patients. However, the current analysis was performed using a central reader, which ensured consistent and homogeneous PSG scoring. It should also be noted that arousals shorter than 15 s were not included in the count of fragmentation, representing another limitation. Because the cerebrospinal fluid hypocretin-1 status of the patients in this study was not known, interpretation of the findings with regard to specific narcolepsy types is limited. While this analysis could also potentially be criticized for an absence of a 'normal' control group that would provide a relevant frame of reference for the transitional indices, the purpose was to expand the knowledge of the effects of SXB on DNS, with the placebo serving as an adequate comparative control. Finally, this analysis reflects only an 8-week exposure to SXB and, as previously noted, longer duration of treatment may result in different effects. Nevertheless, these results show consistency with findings from previous PSG evaluations of changes in sleep architecture related to DNS with SXB (Boscolo-Berto et al., 2012; Dauvilliers et al., 2014) .
CONCLUSI ON S
In this analysis, SXB showed improvements in PSG and patient-reported measures that were characteristic of DNS in these patients with narcolepsy. SXB 9 g was associated with the greatest effects across the PSG outcomes as well as for patient-reported nocturnal sleep quality. There were significantly fewer shifts to Stage N1/Wake from both REM and NREM sleep stages, but further evaluation is needed to determine the contribution of these sleep stage shifts to the fragmented sleep characteristic of narcolepsy, as well as the pathways by which SXB exerts its observed effects on consolidating sleep and ameliorating DNS.
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